A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors

Stacy L. Moulder, John J. Mahany, Richard Lush, Caio Rocha-Lima, Michael Langevin, Karen J. Ferrante, Lisa Michele Bartkowski, Shama M. Kajiji, Dennis A. Noe, Simone Paillet, Daniel M. Sullivan

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Purpose: The purpose of this phase I clinical trial was to determine the maximum-tolerated dose and toxicity of CP-609,754 in patients with solid tumors refractory to standard therapies, to determine the cellular effects of CP-609,754 on its molecular target (farnesyltransferase), and to determine the recommended phase II dose (RP2D) of this agent. Experimental Design: Consenting patients with adequate bone marrow, liver, and renal function were enrolled with an accelerated dose strategy with single-patient parallel cohorts in whom the drug was given orally either once or twice daily. Once a dose-limiting toxicity was encountered or two patients developed Common Toxicity Criteria ≥ grade 2 toxicities, a modified Fibonacci sequence was initiated. Blood samples were collected during cycle 1 for pharmacokinetic and pharmacodynamic analyses. Results: A total of 68 cycles of CP-609,754 was administered to 21 patients enrolled in this study. The dose escalation was from 20 mg once daily to 640 mg twice per day, and at the highest dose level, one of six patients developed a dose-limiting toxicity of grade 3 neuropathy. The drug was otherwise well tolerated, and the maximum-tolerated dose was not reached because of the large number of tablets that would have been required for additional dose escalation. Pharmacokinetic analyses showed a proportional increase in exposure with dose, rapid oral absorption, and a half-life of ∼3 hours. Pharmacodynamic results predict a 95% maximal inhibition of peripheral blood mononuclear cell farnesyltransferase activity 2 hours postdose, on average, with a dose of 400 mg twice per day of CP-609,754. Conclusions: On the basis of the safety findings and the pharmacokinetic and pharmacodynamic analyses, the RP2D of CP-609,754 is ≥640 mg twice per day.

Original languageEnglish (US)
Pages (from-to)7127-7135
Number of pages9
JournalClinical Cancer Research
Issue number21
StatePublished - Nov 1 2004
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors'. Together they form a unique fingerprint.

Cite this